These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23647062)

  • 1. Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
    Celegato M; Borghese C; Casagrande N; Carbone A; Colombatti A; Aldinucci D
    Leuk Lymphoma; 2014 Jan; 55(1):149-59. PubMed ID: 23647062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
    Kashkar H; Deggerich A; Seeger JM; Yazdanpanah B; Wiegmann K; Haubert D; Pongratz C; Krönke M
    Blood; 2007 May; 109(9):3982-8. PubMed ID: 17185461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
    Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.
    Aldinucci D; Celegato M; Borghese C; Colombatti A; Carbone A
    Br J Haematol; 2011 Jan; 152(2):182-90. PubMed ID: 21114485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
    Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
    Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.
    Aldinucci D; Rapana' B; Olivo K; Lorenzon D; Gloghini A; Colombatti A; Carbone A
    Br J Haematol; 2010 Jan; 148(1):115-8. PubMed ID: 19821826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
    Zhao WL; Liu YY; Zhang QL; Wang L; Leboeuf C; Zhang YW; Ma J; Garcia JF; Song YP; Li JM; Shen ZX; Chen Z; Janin A; Chen SJ
    Blood; 2008 Apr; 111(7):3867-71. PubMed ID: 18235046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
    Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
    Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
    Shang J; Chen ZZ; Wu WB; Wei TN; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):911-6. PubMed ID: 23363746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
    Blum KA; Johnson JL; Niedzwiecki D; Canellos GP; Cheson BD; Bartlett NL
    Leuk Lymphoma; 2007 Jul; 48(7):1313-9. PubMed ID: 17613759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
    Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
    Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin lymphoma: Pathology and biology.
    Mathas S; Hartmann S; Küppers R
    Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.